Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Every story we pull is tagged to the disease it’s about — so you can filter to your condition and read only what matters.
Showing news related to
pediatric inspired usc all regimen vs hyper cvad in adults with ph negative and ph like acute lymphoblastic leukemia
Original title: “Pediatric-inspired USC-ALL regimen vs hyper-CVAD in adults with Ph-negative and Ph-like acute lymphoblastic leukemia.”
infectious complications of treatment for acute lymphoblastic leukemia in adults is antifungal prophylaxis necessary a single center retrospective cohort study
Original title: “Infectious complications of treatment for acute lymphoblastic leukemia in adults: Is antifungal prophylaxis necessary? A single-center retrospective cohort study.”
By delivering the genetic instructions ... T-cell-engaging therapeutics with the potential convenience and durability of a one-time treatment. VNX-101 has received U.S. FDA Fast Track, Orphan Drug, and Rare Pediatric Disease designations. ... The SENTRY-CD19 Clinical Trial [NCT06533579] ... By delivering the genetic instructions for therapeutic protein production directly in vivo, Vironexis is developing an approach intended to combine the potency of T-cell-engaging therapeutics with the potential convenience and durability of a one-time treatment. VNX-101 has received U.S. FDA Fast Track, Orphan Drug, and Rare Pediatric Disease designations. ... The SENTRY-CD19 Clinical Trial [NCT06533579] is a Phase 1/2, first-in-human, open-label, dose-escalating study designed to assess the safety and efficacy of VNX-101 in patients with relapsed or refractory CD19 positive hematologic malignancies. Visit the clinicaltrials.gov listing for more information on the trial. ... Vironexis Biotherapeutics is a clinical-stage biotechnology company developing in vivo therapies designed to enable the body to produce therapeutic proteins following a single administration. Our platform is being developed across oncology and other serious diseases with the goal of transforming medicines that traditionally require repeated administration into durable, potentially one-time therapies. Mr. Varma continued, “Further, we believe VNX-101 has achieved an important first for the field: demonstrating that a systemically delivered, one-time in vivo therapy can translate into clinical antitumor activity in patients with blood cancer and extramedullary disease.” “These three patients have tried multiple lines of therapy and, sadly, exhausted available treatment options. We believe the depth, consistency, and emerging durability of these responses provide important clinical validation of our in vivo therapeutic protein platform, and compelling proof of concept for its potential to transform the body into a meaningful, durable source of highly active cancer therapeutics.”
Original title: “Vironexis Announces Complete and Durable Responses in Relapsed/Refractory ALL Patients Treated with VNX-101 - BioSpace”
outcomes of pediatric precursor b cell acute lymphoblastic leukemia a tertiary care cancer center experience from a lower middle income country
Original title: “Outcomes of Pediatric Precursor B Cell Acute Lymphoblastic Leukemia: A Tertiary Care Cancer Center Experience from a Lower-Middle-Income Country.”
genetic predisposition of asparaginase induced hypertriglyceridemia in children with acute lymphoblastic leukemia two case reports and review of literature
Original title: “Genetic predisposition of Asparaginase-induced hypertriglyceridemia in children with acute lymphoblastic leukemia: Two case reports and review of literature.”
disseminated ganciclovir resistant cytomegalovirus in a nontransplant pediatric all patient a case report
Original title: “Disseminated Ganciclovir-Resistant Cytomegalovirus in a Nontransplant Pediatric ALL Patient: A Case Report.”
comprehensive genomic analysis of five kindreds with multiple childhood leukemias importance of individual functional analysis for rare etv6 germline variants
Original title: “Comprehensive genomic analysis of five kindreds with multiple childhood leukemias: importance of individual functional analysis for rare ETV6 germline variants.”
Emily Curran, MD, University of Cincinnati, calls for decentralized trials and stronger community-academic ties to widen ALL patient access. Although trials are essential for advancing new treatments, Curran noted that strict eligibility criteria, put in place for safety, often exclude patients with impaired kidney function, even when a treatment is not renally cleared or in prior lines of therapy. In practice, this leaves clinicians making treatment decisions for real-world patients without the benefit of trial data to guide them. Practical nuances, such as when to hold or dose-reduce a drug, rarely make it into published manuscripts. Compounding this, the pace of change in the field means that by the time findings are published, treatment approaches may have already evolved, leaving published literature outdated almost as soon as it appears. Looking ahead, Curran pointed to decentralized clinical trials as a promising solution, allowing patients to receive care locally through their own oncologists, supplemented by virtual or occasional in-person visits rather than requiring travel to a central site. Patients who enroll tend to be those willing and able to participate, and mistrust of clinical research means some communities remain · underrepresented. Geography compounds the problem: patients living hours from a trial site may be unable to commit to visits spanning multiple consecutive days, even when institutions offer support such as discounted hotel stays. Part 1: What Now Predicts Outcomes in Older Adults With ALL: Emily K. Curran, MD · Part 2: Rethinking ALL Treatment for Older Adults: Emily K. rare disease cases, helping extend expert-guided care to patients regardless of where they live.
Original title: “Clinical Trials Leave Many ALL Patients Behind: Emily K. Curran, MD | AJMC”
znf184 negatively regulates hr repair and predicts poor prognosis in acute lymphoblastic leukemia
Original title: “ZNF184 negatively regulates HR repair and predicts poor prognosis in acute lymphoblastic leukemia.”
Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment landscape of relapsed/refractory (R/R) B-cell precursor acute lymphoblastic leukemia (B-ALL), with high remission rates across various CAR T-cell constructs. However, the durability of these responses remains a ... Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment landscape of relapsed/refractory (R/R) B-cell precursor acute lymphoblastic leukemia (B-ALL), with high remission rates across various CAR T-cell constructs. However, the durability of these responses remains a major challenge, with many patients experiencing relapse after an initial remission. Bone Marrow Transplantation - CAR T-cell therapy in patients with acute lymphoblastic leukemia: a systematic review and meta-analysis This systematic review and meta-analysis aimed to compare the efficacy and safety of different CAR T-cell constructs across 40 clinical trials, including a total of 1540 R/R B-ALL patients. We assessed the impact of patient demographics, prior treatment exposure, and construct characteristics on treatment outcomes. The pooled complete remission rate (CRR) was 83.4% (I2 = 49%), with a minimal residual disease-negative complete remission (MRDneg-CR/CRi) rate of 92.7% (I2 = 48%). Factors associated with the clinical outcome of patients with relapsed/refractory CD19 + acute lymphoblastic leukemia treated with ARI-0001 CART19-cell therapy. J Immunother Cancer. 2021;9:e003644 https://doi.org/10.1136/jitc-2021-003644. ... Myers RM, Taraseviciute A, Steinberg SM, Lamble AJ, Sheppard J, Yates B, et al. Blinatumomab nonresponse and high-disease burden are associated with inferior outcomes after CD19-CAR for B-ALL.
Original title: “CAR T-cell therapy in patients with acute lymphoblastic leukemia: a systematic review and meta-analysis | Bone Marrow Transplantation”
Pharmacy Times offers the latest news and insights for the pharmacy professional and solutions that impact the everyday practice of pharmacy. The conversation begins with an overview of the current burden of ALL and limitations associated with traditional treatment approaches, setting the stage for how cellular therapies are reshaping care for patients with relapsed or refractory disease. The speakers then examine the mechanism of action and clinical trial data supporting obe-cel, highlighting how its design may influence efficacy and safety outcomes compared with earlier CAR T products. Throughout the discussion, the panel emphasizes practical considerations for pharmacists, including toxicity recognition and management, adverse event monitoring, and interdisciplinary coordination across transplant and cellular therapy teams. The episode underscores the critical role of oncology pharmacists in translating clinical trial evidence into real-world practice and supporting the safe integration of novel CAR T-cell therapies into evolving treatment paradigms for ALL. Tatyana Grgich, PharmD, BCOP, CPP, is a stem cell transplant and cell therapy pharmacist and pharmacy specialist at USC Medical Center. Jacqueline Del Pena, PharmD, is a clinical pharmacy specialist at Memorial Sloan Kettering Cancer Center, focusing on adult cell therapy services. Catie Cash, PharmD, BCOP, is a stem cell transplant and cell therapy pharmacist at Duke University Hospital. Rebecca Gonzalez, PharmD, BCOP, FASTCT, is a clinical pharmacist specialist in bone marrow transplant and cellular therapy at Moffitt Cancer Center.
Original title: “Pharmacist Takeover: CAR T Therapy Signals a Shift in ALL Treatment | Pharmacy Times”
Real-world inotuzumab ozogamicin boosts remission in relapsed/refractory B-cell ALL, supports transplant, and flags sinusoidal obstruction syndrome risk. Reasonable remission rates were seen when inotuzumab ozogamicin was administered as a salvage therapy to patients with relapsed/refractory B-cell · acute lymphoblastic leukemia (B-ALL), with mean (SD) survival rates of 51.7% (8.1%) overall and 32.4% (8.0%) event-free, according to new research in · Blood Cancer Journal.1 These real-world data are helping to fill a data gap for such evidence currently left by limited studies in this disease and medication, which have been concentrated in clinical trial settings.2-4 Depth of response was clinically meaningful: MRD-negative status occurred in 71.4% of CR/CRi patients, enabling consolidation with ASCT or CAR T in 67.8% overall. Post-therapy hepatic SOS/veno-occlusive disease remained a major toxicity signal, with 9/10 cases after transplant and no clear correlation with cumulative dose or IO–transplant interval. European LeukemiaNet criteria. Of this group, 71.4% (n = 20) reached minimal residual disease–negative status, and 67.8% (n = 19) followed inotuzumab ozogamicin with allogeneic stem cell transplant (ASCT; n = 18) or chimeric antigen receptor (CAR) T-cell therapy (n = 1). Inotuzumab ozogamicin versus FLAG-Ida in the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia – real-world resource use data. Leuk Lymphoma. 2020;61(2):491-493. doi:10.1080/10428194.2019.1672057 · Molina O, Bataller A, Thampi N, et al. Near-haploidy and low-hypodiploidy in B-cell acute lymphoblastic leukemia: when less is too much. Cancers (Basel). 2021;14(1):32. doi:10.3390/cancers14010032 · Hepatic sinusoidal obstruction syndrome (veno-occlusive disease) in adults.
Original title: “Inotuzumab Ozogamicin Outcomes in ALL Validated Outside of Clinical Trials | AJMC”